脑机接口+CRO概念+减肥药+医疗器械概念+人民币贬值受益 1、根据2025年12月12日互动易：公司正与下游脑机接口客户深入开展产品合作，协助客户实现从实验 室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小，具体客户合作细节涉及商业 机密不便回复。 异动分析 来源：新浪证券-红岸工作室 2、2023年9月1日公告：公司专注于医疗器械领域，为全球医疗器械百强客户以及细分市场龙头企业提 供CDMO和CRO的一站式服务。 2月10日，美好医疗跌1.31%，成交额1.88亿元，换手率1.59%，总市值180.50亿元。 3、2025年10月22日投资者关系记录表：公司已与客户签订减肥笔订单，相关自动化产线已启动建设， 预计明年投入交付。 公司简介 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-1645.77万，占比0.09%，行业排名129/137，该股当前无连续增减仓现象，主力趋势不 明显；所属行业主力净流入-3.33亿，连续2日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-1645.77万-2813.67万-379 ...

Core Viewpoint - The company, Sichuan Portong Medical Equipment Group Co., Ltd., specializes in medical gas equipment and cleanroom systems, with a focus on providing comprehensive engineering solutions for medical institutions [3]. Group 1: Company Overview - Sichuan Portong Medical Equipment Group Co., Ltd. was established on January 13, 1998, and went public on July 25, 2023 [7]. - The company's main business includes the research, design, manufacturing, integration, and operation services of medical gas equipment and cleanroom systems [3][7]. - The revenue composition of the company is as follows: cleanroom equipment and systems 55.69%, medical gas equipment and systems 37.30%, sales of medical devices and other products 4.06%, operation services 2.81%, and others 0.14% [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved operating revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to the parent company of -10.21 million yuan, a year-on-year decrease of 150.92% [8]. - The company has distributed a total of 48.9973 million yuan in dividends since its A-share listing [9]. Group 3: Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in the evaluation of small and medium-sized enterprises in China [3]. - The company is positioned within the pharmaceutical and biological industry, specifically in the medical device sector [8]. Group 4: Recent Developments - The company has developed the Portong Cloud Monitoring Platform, which utilizes advanced IoT technology to provide real-time monitoring solutions for medical equipment in hospitals [2]. - The company’s medical gas equipment and cleanroom systems are crucial for ensuring the safety and cleanliness standards required for brain-computer interface surgeries [2].

Core Viewpoint - The company, Canar Medical, has seen a stock price increase of 3.14% with a trading volume of 140 million yuan and a market capitalization of 3.897 billion yuan, benefiting from the depreciation of the RMB and its focus on the medical device sector, particularly in assisted reproduction [1][2][3]. Company Overview - Canar Medical Co., Ltd. specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables. The main products include puncture needles, syringes, laboratory consumables, and masks [2][7]. - The company began supplying IVF culture tubes to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproduction market [2]. - As of January 30, the number of shareholders is 6,957, a decrease of 2.08%, with an average of 10,872 circulating shares per person, an increase of 2.13% [7]. Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Market Position and Trends - The company has a high overseas revenue ratio of 90.61%, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 28.77 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak. The current stock price is near a support level of 31.49 yuan, which is critical for potential rebound or further decline [6].

Core Viewpoint - The pharmaceutical retail market is transitioning towards high-quality development, with significant growth opportunities anticipated in various segments, including traditional Chinese medicine, medical devices, and innovative drugs [17][22][46]. Market Overview - The retail scale of China's physical pharmacies for January to November 2025 is projected to reach 557.7 billion yuan, showing a slight year-on-year decline of 0.8%. However, the cumulative scale for October and November is expected to be 108.7 billion yuan, reflecting a year-on-year growth of 4.0% [22][30]. - The pharmaceutical retail market is experiencing a recovery phase, driven by ongoing healthcare reforms and the optimization of market structures, which are expected to enhance the industry's long-term growth prospects [22][30]. Category Analysis - **Pharmaceuticals**: The cumulative scale for pharmaceuticals from January to November 2025 is estimated at 453.4 billion yuan, with a year-on-year growth of 0.4%. The sales scale for October and November is projected to be 88 billion yuan, with a year-on-year increase of 5.5% [29]. - **Traditional Chinese Medicine (TCM)**: The cumulative scale for TCM from January to November 2025 is expected to be 42.9 billion yuan, reflecting a year-on-year decline of 4.2%. However, November shows a month-on-month growth of 12.5% [30]. - **Medical Devices**: The cumulative scale for medical devices is projected to be 26.1 billion yuan, with a slight year-on-year decline of 0.4%. The sales scale for October and November is expected to show a year-on-year growth of 6.3% [37]. - **Health Products**: The cumulative scale for health products is anticipated to be 21 billion yuan, with a year-on-year decline of 15.7%. However, November shows signs of recovery with a month-on-month growth of 5.3% [34]. Investment Opportunities - The pharmaceutical sector is expected to benefit from a low valuation environment, with public funds showing low allocation to the sector. The anticipated recovery in macroeconomic factors and the demand for major products are expected to drive growth in the industry [15]. - The innovative drug sector is transitioning from quantity to quality, with a focus on differentiated products and internationalization. Companies with strong pipelines and the ability to deliver profits are recommended for investment [15][46]. - The medical device market is witnessing a recovery in bidding volumes, with ongoing updates and international expansion opportunities. Companies focusing on innovation and product upgrades are expected to perform well [46]. Specific Product Trends - **Top Chemical Drugs**: In October and November 2025, the top 20 chemical drug categories accounted for 78.3% and 80.0% of the market share, respectively, with significant growth in categories such as anti-tumor drugs and systemic antiviral drugs [40][41]. - **Top Traditional Chinese Medicine Products**: The market share for TCM in November reached 86.4%, with notable growth in cold medications and cough remedies [44][45]. Conclusion - The pharmaceutical retail market is poised for a significant transformation, with various segments showing potential for growth. The ongoing reforms and market dynamics are expected to create a favorable environment for investment in the pharmaceutical and healthcare sectors [22][30][46].

来源：北 京日报客户端 近日，2026中关村论坛系列活动——第九届中关村国际前沿科技大赛金融科技领域复赛在中关村（西 城）金融科技特色产业园新动力金融科技中心举办。 比赛现场，来自高校院所、投资机构、相关企业的多位专家受邀担任评委，针对路演表现和发展前景进 行现场打分，并对项目未来的发展方向提出了建设性意见和建议。 中关村国际前沿科技大赛创设于2017年，把握全球科技革命和产业变革方向，密切跟踪前沿科技发展趋 势，按照"全球邀约、自由探索、公开路演"的方式，搭建高水平国际前沿科技交流竞技平台。本届大赛 共设立AI底层技术、AI应用、创新药、医疗器械、新材料、文化科技、金融科技等七个参赛领域，共 征集境内外项目2168项，其中金融科技领域申报198项，经初赛评审后共有25个项目进入复赛，涉及区 块链与分布式账本应用、数智化金融营销、金融数据安全与合规技术、支付欺诈实时防火墙系统等多个 技术方向。 最终，面向金融的超快速数据传输解决方案、桔吉机器人会计等10个项目脱颖而出，获得第九届中关村 国际前沿科技大赛金融科技领域TOP10荣誉称号。 SEX 117 公司概况-全国布局 IT 提供专业。迅捷、可信赖的全生食用 ...

Core Viewpoint - Spring Medical experienced a decline of 1.24% on February 4, with a trading volume of 49.12 million yuan and a total market capitalization of 8.834 billion yuan [1] Company Overview - Spring Medical is a leading domestic orthopedic medical device manufacturer, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is currently in the design and inspection phase for a customized porous tantalum dental implant product [2] - Spring Medical has obtained registration certificates for hip and knee surgical robots and medical image processing software, indicating its investment in smart medical technology [2][3] Industry Position - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in the national evaluation of small and medium-sized enterprises, highlighting its strong innovation capabilities and market share [3] - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [5][8] Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan in the last three years [8] Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Central European Economic Selection Mixed A, both of which are new shareholders [9]

发布时间：2026-02-02 行业投资评级 强于大市|维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 8338.3 | | 52 周最高 | 9323.49 | | 52 周最低 | 6876.88 | 行业相对指数表现 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 2025-02 2025-04 2025-06 2025-09 2025-11 2026-01 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:徐智敏 SAC 登记编号:S1340525100003 Email: xuzhimin@cnpsec.com 近期研究报告 2025 年有数十个 AI 衍生的管线进入人体临床试验，但回顾过往 管线来看，与任何其他新技术的发展一样，AI 制药的发展之路也是曲 折的。AI 制药极大加速了临床早期的进程同时亦能取得超出传统经验 水平的 1 期成功率（80%~90% vs 40%~65%），而在 2 期及后续的进 ...

（来源：经济日报） 上海农商银行"捐赠 +"是促进早期科技成果转化的创新模式，与上海理工大学的合作聚焦医工交叉领域 产业化发展与医疗器械概念验证工程化中心建设两大重点方向。在实施捐赠的同时，上海农商银行还联 动政府部门、投资机构、产业园区等多方生态圈资源，为早期科研项目提供从资金支持、技术验证到市 场对接的全链条服务，全力破解科技成果转化"最初一公里" ，着力打造科创客户全周期服务体系，建 设科技金融"线上+线下"生态圈，深化行业金融专业支撑，坚持"向早、向小、向硬"，持续探索科技金 融服务的"无人区"。 转自：经济日报 未来，上海农商银行将聚焦"捐赠 +"项目全生命周期需求深化合作，提供覆盖公司成立前后的金融服务 与孵化赋能，配套人才服务等增值支持，同时激活专家库资源，推动更多科研成果落地转化，共同为上 海科创产业高质量发展注入动力。（经济日报记者 李治国） 1月28日，上海农商银行创新推出的、旨在推动早期科研转化的"捐赠+"模式首期10个项目落地。 据了解，2025年6月，上海农商银行与上海理工大学签署早期科技成果转化"捐赠+"合作方案，共建成果 转化赋能生态圈。合作以来，双方聚焦医学前沿与临床需求，从1 ...

消息面:现货黄金首次突破5200美元/盎司，年内累计涨幅超过20%。大规模冬季风暴引发美国天然气价 格飙涨，创三年来最高。多家品牌金饰克价大幅上调 老凤祥克价1620元。 欢迎您在评论中分享自己的看法，大家一起学习和讨论。 贵金属高开高走，截止午盘大涨10.26%，其中晓程科技20CM涨停，恒邦股份、招进黄金、四川黄金等 多股涨停。采掘行业、珠宝首饰、黄金概念、有色金属、稀缺资源等行业板块紧随其后，且涨幅均在 4%上方。 光伏设备低开低走陷入调整，截止午盘下跌2.74%，其中高测股份大跌8.1%，迈为股份、东方日升、泽 润新能等多股跌幅在7%上方。痘病毒防治、重组蛋白、生物制品、医疗器械等行业板块紧随其后，且 跌幅均在2%上方。 探底回升后回到中轴附近，截止午盘沪指上涨0.49%，深成指上涨0.09%，创业板指下跌0.37%。两市合 计超3500只个股上涨，合计成交额1.93万亿。 ...

Group 1 - The core viewpoint of the news is that 嘉事堂's stock has experienced fluctuations, with a recent decline of 2.02% and a current price of 16.50 yuan per share, while the company has seen a year-to-date increase of 14.90% [1] - As of January 9, 嘉事堂's shareholder count has increased by 50% to 36,000, while the average circulating shares per person decreased by 33.33% to 8,096 shares [2] - 嘉事堂's main business involves pharmaceutical wholesale and retail, with commercial revenue accounting for 100% of its income [1] Group 2 - For the period from January to September 2025, 嘉事堂 reported a revenue of 14.459 billion yuan, representing a year-on-year decrease of 21.80%, and a net profit attributable to shareholders of 141 million yuan, down 38.81% year-on-year [2] - 嘉事堂 has been listed on the stock market since August 18, 2010, and has distributed a total of 874 million yuan in dividends since its A-share listing, with 216 million yuan distributed in the last three years [2] - The company operates within the pharmaceutical and biological industry, specifically in the pharmaceutical commercial sector, and is involved in various concept sectors including pharmaceutical e-commerce and state-owned enterprise reform [2]